← Back
Data updated: Mar 10, 2026
DECIPHERA PHARMS
OncologyGastroenterology
DECIPHERA PHARMS is a pharmaceutical company focused on Oncology, Gastroenterology. Key products include QINLOCK.
2020
Since
2
Drugs
-
Trials
3
Approved (2yr)
Key Drugs
Recent Activity
ROMVIMZA 2025-12-12
Labeling
QINLOCK 2025-05-06
Labeling
ROMVIMZA 2025-02-14
Type 1 - New Molecular Entity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 67%
2 drugs
Gastroenterology 33%
1 drugs
Pipeline Strength Pro
Loading...